Sellas Life Sciences Stock Discussion

$Sellas Life Sciences (SLS.US)$
SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia
Tuesday, 10th December at 8:30 am
-  Study Reaches Pre-Specified Threshold of 60 Events (Deaths) Initiating the Interim Analysis –
-  REGAL Independent Data Monitoring Committee to Perform Interim Analysis in January 2025 -
-  Company to Host Webcast Call Today at 9:00 am ET
NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: ...

$Sellas Life Sciences (SLS.US)$ SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML
2 MINUTES AGO, 8:45 AM EST
VIA GLOBENEWSWIRE
Median Overall Survival (mOS) Not Yet Reached, Now Exceeds 7.7. Months at Latest Follow-Up in the 30 mg BIW Cohort in Patients Relapsed or Refractory to Venetoclax-Based Regimens -
- Overall Response Rate (ORR) of 56% Achieved to Date in Patient with Acute Myeloid Leukemia with Myelodysplasia Relat...

$Sellas Life Sciences (SLS.US)$
SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML
Monday, 9th December at 8:45 am
- Median Overall Survival (mOS) Not Yet Reached, Now Exceeds 7.7. Months at Latest Follow-Up in the 30 mg BIW Cohort in Patients Relapsed or Refractory to Venetoclax-Based Regimens -
- Overall Response Rate (ORR) of 56% Achieved to Date in Patient with Acute Myeloid Leukemia with Myelodysplasia Related Changes (AM...

$Sellas Life Sciences (SLS.US)$
“SELLAS Life Sciences To Present Phase 2a Data On SLS009 For Relapsed/Refractory AML At ASH 2024, Showing 50% Response Rate And Median OS Of 5.5 Months At Selected Doses”

$Sellas Life Sciences (SLS.US)$ Reuters· 2 mins ago
Sellas: Asxl1 Mutations Predictably Identified in Colorectal Cancer and Non-Small Cell Lung Cancer in Addition to Hematologic Malignancies

$Sellas Life Sciences (SLS.US)$
SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers
1 minute ago, 5:45 AM PST
Via GlobeNewswire
- Preselection Method for Cancers Responding to SLS009: High Efficacy of SLS009 Observed in 67% of ASXL1 Mutated Solid Cancers vs 0% in Non-ASXL1 Mutated Cancers –
- ASXL1 Mutations Predictably Identified in Colorectal Cancer (CRC MSI-H) and Non-Small Cell Lung Cancer (NSCLC) in Add...

$Sellas Life Sciences (SLS.US)$ try in the houseeeee

$Sellas Life Sciences (SLS.US)$ Reuters· 1 min ago
Sellas Announces U.S. FDA Rare Pediatric Disease Designation (Rpdd) Granted to Galinpepimut-S (Gps) for the Treatment of Pediatric Acute Myeloid Leukemia

$Sellas Life Sciences (SLS.US)$
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia
SELLAS Life Sciences Group (NASDAQ: SLS) has received Rare Pediatric Disease Designation (RPDD) from the FDA for Galinpepimut-S (GPS) in treating pediatric acute myeloid leukemia (AML). GPS, an immunotherapeutic targeting Wilms Tumor-1, is currently in a Phase 3 REGAL trial for adult AML patients, with an inte...